Bepotastine
From Self-sufficiency
File:Bepotastine.png | |
Systematic (IUPAC) name | |
---|---|
4-[4-[(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid | |
Clinical data | |
Pregnancy category |
|
Routes of administration | Oral, topical (eye drops) |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability |
High (oral) Minimal (topical) |
Protein binding | ~55% |
Excretion | Renal (75–90%) |
Identifiers | |
CAS Number | 125602-71-3 |
ATC code | none |
PubChem | CID 2350 |
DrugBank | DB04890 |
ChemSpider | 2260 |
Chemical data | |
Formula | C21H25ClN2O3 |
Molar mass | 388.88 g/mol[[Script error: No such module "String".]] |
Script error: No such module "collapsible list". |
Bepotastine (Talion) is an antihistamine. It was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name TALION. TALION was co-developed by Tanabe Seiyaku and Ube Industries, Ltd., who discovered bepotastine. In 2001, Tanabe Seiyaku granted Senju exclusive worldwide rights, with the exception of certain Asian countries, to develop, manufacture and market bepotastine for ophthalmic use. Senju, in turn, has granted the US rights for the ophthalmic preparation to ISTA Pharmaceuticals, Inc., a specialty pharmaceutical company located in Irvine, CA.
This pharmacology-related article is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Pages with broken file links
- Drugs with non-standard legal status
- Infobox drug tracked parameters
- Articles without EBI source
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- Organochlorides
- Pyridines
- Piperidines
- Ethers
- H1 receptor antagonists
- Leukotriene antagonists
- Pharmacology stubs
- 2Fix